Brokerages Set Solventum Corporation (NYSE:SOLV) Price Target at $93.70

Shares of Solventum Corporation (NYSE:SOLV) have been given an average rating of “Moderate Buy” by the twelve ratings firms that are covering the firm, Marketbeat reports. Five investment analysts have rated the stock with a hold recommendation and seven have assigned a buy recommendation to the company. The average 12 month price target among brokers that have covered the stock in the last year is $93.70.

Several analysts recently weighed in on SOLV shares. Zacks Research lowered Solventum from a “strong-buy” rating to a “hold” rating in a report on Monday, December 1st. KeyCorp increased their target price on Solventum from $97.00 to $99.00 and gave the stock an “overweight” rating in a report on Friday, February 27th. Weiss Ratings reiterated a “hold (c)” rating on shares of Solventum in a research report on Tuesday, January 27th. BTIG Research reiterated a “buy” rating and issued a $100.00 price target on shares of Solventum in a report on Friday, February 27th. Finally, Mizuho set a $100.00 price objective on Solventum and gave the stock an “outperform” rating in a research note on Tuesday, January 20th.

Solventum Price Performance

Shares of SOLV stock opened at $68.64 on Wednesday. The firm has a fifty day moving average of $75.84 and a two-hundred day moving average of $75.94. The firm has a market cap of $11.91 billion, a P/E ratio of 7.74, a P/E/G ratio of 1.10 and a beta of 0.40. Solventum has a 1-year low of $60.70 and a 1-year high of $88.20. The company has a debt-to-equity ratio of 1.00, a current ratio of 1.23 and a quick ratio of 0.89.

Solventum (NYSE:SOLV) last issued its earnings results on Thursday, February 26th. The company reported $1.57 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.50 by $0.07. Solventum had a net margin of 18.69% and a return on equity of 25.26%. The business had revenue of $2 billion for the quarter, compared to analyst estimates of $1.96 billion. During the same quarter in the prior year, the business posted $1.41 EPS. The company’s revenue for the quarter was down 3.7% on a year-over-year basis. Solventum has set its FY 2026 guidance at 6.400-6.600 EPS. As a group, research analysts anticipate that Solventum will post 6.58 earnings per share for the current fiscal year.

Solventum announced that its board has authorized a stock repurchase plan on Thursday, November 20th that allows the company to buyback $1.00 billion in shares. This buyback authorization allows the company to reacquire up to 7.5% of its stock through open market purchases. Stock buyback plans are typically an indication that the company’s board of directors believes its shares are undervalued.

Insider Buying and Selling at Solventum

In other Solventum news, Director Amy Mcbride Wendell purchased 1,475 shares of Solventum stock in a transaction dated Tuesday, March 10th. The shares were bought at an average cost of $68.03 per share, for a total transaction of $100,344.25. Following the transaction, the director owned 5,039 shares in the company, valued at $342,803.17. This represents a 41.39% increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 0.05% of the company’s stock.

Institutional Investors Weigh In On Solventum

Institutional investors and hedge funds have recently bought and sold shares of the business. Hilltop National Bank lifted its holdings in Solventum by 71.3% in the fourth quarter. Hilltop National Bank now owns 310 shares of the company’s stock worth $25,000 after acquiring an additional 129 shares during the last quarter. CrossGen Wealth LLC acquired a new stake in shares of Solventum during the 4th quarter worth approximately $25,000. Measured Wealth Private Client Group LLC acquired a new stake in shares of Solventum during the 3rd quarter worth approximately $25,000. Deseret Mutual Benefit Administrators lifted its holdings in shares of Solventum by 78.7% in the 3rd quarter. Deseret Mutual Benefit Administrators now owns 370 shares of the company’s stock worth $27,000 after purchasing an additional 163 shares during the last quarter. Finally, JNBA Financial Advisors lifted its holdings in shares of Solventum by 205.4% in the 4th quarter. JNBA Financial Advisors now owns 339 shares of the company’s stock worth $27,000 after purchasing an additional 228 shares during the last quarter.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.